• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
  LongeCity
              Advocacy & Research for Unlimited Lifespans

Photo

Positive data in phase 2 study of senolytic UBX1325 in patients with DME

senolytics

  • Please log in to reply
3 replies to this topic

#1 ambivalent

  • Guest
  • 744 posts
  • 167
  • Location:uk
  • NO

Posted 16 August 2022 - 02:43 PM


https://www.ophthalm...tients-with-dme

 

The 12- and 18-week results indicate that a single injection of UBX1325 resulted in significantly greater letter gains and stabilization of retinal structure than the sham treatment, but also likely altered the disease trajectory of these patients who had been on anti-VEGF treatment,” he concluded. “We are greatly encouraged by these findings and look forward to our upcoming 24-week BEHOLD (DME) and 16-week ENVISION (wet AMD) study readouts in the months ahead.”

 


#2 ambivalent

  • Topic Starter
  • Guest
  • 744 posts
  • 167
  • Location:uk
  • NO

Posted 16 August 2022 - 03:55 PM

A little rushed, I should have pasted:

 

"At 18-weeks, a primary analysis set of 54 patients, patients treated with UBX1325 had a mean improvement in BCVA of +6.1 ETDRS letters from baseline compared to +1.1 EDTRS letters in sham-treated patients (p = 0.0368). Patients treated with UBX1325 had a mean change in CST of +3.2 μm from baseline compared to +53.5 μm in sham-treated patients (p = 0.0719) "

 

CST ~ central subfield thickness.


  • like x 1

#3 ambivalent

  • Topic Starter
  • Guest
  • 744 posts
  • 167
  • Location:uk
  • NO

Posted 23 August 2022 - 06:13 PM

For anyone following this company, contempating investing - be warned.

 

https://www.longecit...d-immortalists/



#4 ambivalent

  • Topic Starter
  • Guest
  • 744 posts
  • 167
  • Location:uk
  • NO

Posted 01 November 2022 - 01:16 PM

24 week data:

 

https://ir.unitybiot...ek-data-phase-2

 

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment

 

UBX1325 maintained stabilization of retinal structure, as measured by central subfield thickness (CST) at 24 weeks, as compared to worsening from baseline in sham-treated patients

 

The proportion of rescue-free patients in the UBX1325-treated arm was 59.4% at 6 months after a single injection, as compared to only 37.5% in the sham-treated arm

 


Edited by ambivalent, 01 November 2022 - 01:16 PM.






Also tagged with one or more of these keywords: senolytics

1 user(s) are reading this topic

0 members, 1 guests, 0 anonymous users